Skip Ribbon Commands
Skip to main content

  ​

​Clinical Trials

Are you suffering from symptoms of Ulcerative colitis or Crohn's disease? Is your disease still active? If so, the Baylor Scott & White Center for Inflammatory Bowel Diseases has a number of ongoing research studies that may benefit you.
BSW Center for Inflammatory Bowel Diseases conducts clinical trials of medications that hold the promise of improving the health of patients with Ulcerative Colitis or Crohn's Disease.
Active Trials
Crohn’s Disease

  1. A Multicenter, Randomized, Double-Blind Study to Evaluate Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration
  2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease.
  3. A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991
  4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional Therapies but Have Not Failed Biologic Therapy
  5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433

 


Ulcerative Colitis

  1. A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis
  2. A Phase 3, Multicenter, Open Label-Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
  3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
  4. A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis (UC)
  5. A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 Induction Therapy in patients with moderate-to-severely active ulcerative colitis who have failed previous biologics therapy
  6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis (M14-675)
  7. An open label, long term safety trial of BI 655130 treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials

 

If you would like to learn more, please contact:

Themistocles Dassopoulos, M.D.
Baylor Scott & White Center for Inflammatory Bowel Diseases
(469) 800-7180​

Nazia Iram, MBBS, CCRC
Clinical Research Coordinator
Baylor Research Institute
214-820-9907
Dallas Clinical Trials Office
214-818-9688